Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Front Immunol ; 12: 662307, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34354699

RESUMEN

The treatment of multibacillary cases of leprosy with multidrug therapy (MDT) comprises 12 doses of a combination of rifampicin, dapsone and clofazimine. Previous studies have described the immunological phenotypic pattern in skin lesions in multibacillary patients. Here, we evaluated the effect of MDT on skin cell phenotype and on the Mycobacterium leprae-specific immune response. An analysis of skin cell phenotype demonstrated a significant decrease in MRS1 (SR-A), CXCL10 (IP-10) and IFNG (IFN-γ) gene and protein expression after MDT release. Patients were randomized according to whether they experienced a reduction in bacillary load after MDT. A reduction in CXCL10 (IP-10) in sera was associated with the absence of a reduction in the bacillary load at release. Although IFN-γ production in response to M. leprae was not affected by MDT, CXCL10 (IP-10) levels in response to M. leprae increased in cells from patients who experienced a reduction in bacillary load after treatment. Together, our results suggest that CXCL10 (IP-10) may be a good marker for monitoring treatment efficacy in multibacillary patients.


Asunto(s)
Quimiocina CXCL10/sangre , Leprostáticos/uso terapéutico , Lepra/tratamiento farmacológico , Piel/inmunología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Carga Bacteriana/efectos de los fármacos , Biomarcadores/sangre , Quimiocina CXCL10/inmunología , Quimioterapia Combinada , Femenino , Humanos , Leprostáticos/administración & dosificación , Lepra/inmunología , Masculino , Persona de Mediana Edad , Mycobacterium leprae/inmunología , Piel/microbiología , Piel/patología , Resultado del Tratamiento , Adulto Joven
2.
PLoS Negl Trop Dis ; 14(9): e0008583, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32936818

RESUMEN

BACKGROUND: Subclinical infection with Mycobacterium leprae is one potential source of leprosy transmission, and post-exposure prophylaxis (PEP) regimens have been proposed to control this source. Because PEP trials require considerable investment, we applied a sensitive variation of the kinetic mouse footpad (MFP) screening assay to aid in the choice of drugs and regimens for clinical trials. METHODOLOGY/PRINCIPAL FINDINGS: Athymic nude mice were inoculated in the footpad (FP) with 6 x 103 viable M. leprae and treated by gastric gavage with a single dose of Rifampin (SDR), Rifampin + Ofloxacin + Minocycline (SD-ROM), or Rifapentine + Minocycline + Moxifloxacin (SD-PMM) or with the proposed PEP++ regimen of three once-monthly doses of Rifampin + Moxifloxacin (RM), Rifampin + Clarithromycin (RC), Rifapentine + Moxifloxacin (PM), or Rifapentine + Clarithromycin (PC). At various times post-treatment, DNA was purified from the FP, and M. leprae were enumerated by RLEP quantitative PCR. A regression analysis was calculated to determine the expected RLEP value if 99.9% of the bacilli were killed after the administration of each regimen. SDR and SD-ROM induced little growth delay in this highly susceptible murine model of subclinical infection. In contrast, SD-PMM delayed measurable M. leprae growth above the inoculum by 8 months. The four multi-dose regimens delayed bacterial growth for >9months post-treatment cessation. CONCLUSIONS/SIGNIFICANCE: The delay in discernable M. leprae growth post-treatment was an excellent indicator of drug efficacy for both early (3-4 months) and late (8-9 months) drug efficacy. Our data indicates that multi-dose PEP may be required to control infection in highly susceptible individuals with subclinical leprosy to prevent disease and decrease transmission.


Asunto(s)
Infecciones Asintomáticas/terapia , Leprostáticos/uso terapéutico , Lepra/tratamiento farmacológico , Mycobacterium leprae/efectos de los fármacos , Profilaxis Posexposición/métodos , Animales , Carga Bacteriana/efectos de los fármacos , Claritromicina/uso terapéutico , Combinación de Medicamentos , Lepra/transmisión , Ratones , Ratones Desnudos , Minociclina/uso terapéutico , Moxifloxacino/uso terapéutico , Mycobacterium leprae/crecimiento & desarrollo , Rifampin/análogos & derivados , Rifampin/uso terapéutico
3.
J Antimicrob Chemother ; 72(2): 455-461, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27798204

RESUMEN

OBJECTIVES: The anti-leprosy drug clofazimine has been shown to have antimicrobial activity against Mycobacterium tuberculosis and has been associated with treatment-shortening activity in both clinical and preclinical studies of TB chemotherapy. However, a reported lack of early bactericidal activity (EBA) in TB patients has raised questions regarding the usefulness of clofazimine as an anti-TB drug. Our objective was to systematically evaluate the EBA of clofazimine in vitro and in vivo to provide insight into how and when this drug exerts its antimicrobial activity against M. tuberculosis. METHODS: We evaluated the 14 day EBA of clofazimine (i) in vitro at concentrations ranging from 4 times below to 4 times above the MIC for M. tuberculosis and (ii) in vivo in infected BALB/c mice at doses ranging from 1.5 to 100 mg/kg/day, and serum clofazimine levels were measured. In both experiments, isoniazid was used as the positive control. RESULTS: In vitro, clofazimine, at any concentration tested, did not exhibit bactericidal activity during the first week of exposure; however, in the second week, it exhibited concentration-dependent antimicrobial activity. In vivo, clofazimine, at any dose administered, did not exhibit bactericidal activity during the first week, and limited antimicrobial activity was observed during the second week of administration. While serum clofazimine levels were clearly dose dependent, the antimicrobial activity was not significantly related to the dose administered. CONCLUSIONS: Our data suggest that clofazimine's delayed antimicrobial activity may be due more to its mechanism of action rather than to host-related factors.


Asunto(s)
Antituberculosos/uso terapéutico , Carga Bacteriana/efectos de los fármacos , Clofazimina/uso terapéutico , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis Pulmonar/tratamiento farmacológico , Animales , Antituberculosos/farmacocinética , Clofazimina/farmacocinética , Isoniazida/uso terapéutico , Pulmón/microbiología , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana , Tuberculosis Pulmonar/microbiología
4.
J Wound Care ; 23(8): 417-8, 422-4, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25139600

RESUMEN

OBJECTIVE: Mycobacterium ulcerans is the causative agent of Buruli ulcer disease, the third most common mycobacteriosis after tuberculosis and leprosy and an emerging public health threat in sub-Saharan Africa. The bacteria produce a diffusible cytotoxin called mycolactone, which triggers the formation of necrotic lesions in cutaneous and subcutaneous tissues. The principal aim of this study was to characterise the cell surface hydrophobicity of Mycobacterium ulcerans and determine if bacteria bind to dialkyl carbamoyl chloride (DACC)-coated dressings through hydrophobic interactions in vitro. Since mycolactone displays hydrophobic groups, a secondary aim was to compare mycolactone binding to hydrophobic and standard dressings. METHODS: We used hydrophobic interaction chromatography to evaluate the cell surface hydrophobicity of Mycobacterium ulcerans, compared to that of other microorganisms colonising wounds. The binding of Mycobacterium ulcerans bacteria to DACC-coated and control dressings was then assessed quantitatively by measurement of microbial adenosine triphosphate (ATP), while that of mycolactone was evaluated by fluorescence spectroscopy. RESULTS: Compared to Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa, Mycobacterium ulcerans displayed the highest cell surface hydrophobicity, irrespective of the bacterial production of mycolactone. Mycobacterium ulcerans bacteria bound to DACC-coated dressings [corrected] better than untreated controls. Mycolactone did not bind stably to hydrophobic, nor standard dressings, in the conditions tested. CONCLUSION: Retention of Mycobacterium ulcerans and other wound pathogens to DACC-coated dressings may help reduce the bacterial load in Buruli ulcers and thereby improve healing. Dressings efficiently capturing mycolactone may bring an additional clinical benefit, by accelerating the elimination of the toxin during the course of antibiotic treatment.


Asunto(s)
Adhesión Bacteriana , Vendajes/microbiología , Úlcera de Buruli/microbiología , Carbamatos/administración & dosificación , Mycobacterium ulcerans/fisiología , Cicatrización de Heridas/efectos de los fármacos , Carga Bacteriana/efectos de los fármacos , Úlcera de Buruli/tratamiento farmacológico , Movimiento Celular , Escherichia coli/fisiología , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Macrólidos/metabolismo , Pseudomonas aeruginosa/fisiología , Staphylococcus aureus/fisiología
5.
Int J Dermatol ; 53(7): 873-8, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24601869

RESUMEN

BACKGROUND: The trophic or chronic plantar ulcer of leprosy is one of the principle causes of disability and deformity in the disease and has been given due importance in the evolution of its classification. In view of the diversity of its clinical implications, the World Health Organization was obliged to bring this entity under its remit in order to develop uniform guidelines to be applied around the globe. Despite relentless endeavor, its management continues to represent a dilemma. OBJECTIVES: The role of topical phenytoin sodium in wound healing led this group to evaluate its efficacy in the healing of trophic or chronic plantar ulcers. The success of the therapy was assessed according to the extent of regression in the size of the ulcer(s) following the formation of granulation tissue. METHODS: Forty patients released from leprosy control were recruited. A retrospective diagnosis was made in each case, and patients were grouped accordingly. Demographic data were recorded after the provision of informed consent. Bacterial cultures before and after treatment, and radiography were performed in each case. A phenytoin sodium fine powder zinc oxide paste dressing was applied every day for four weeks. Granulation was graded according to its appearance in order to evaluate the success of the topical therapy. RESULTS: Of the 40 patients, 26 (65.0%) borderline lepromatous leprosy patients had trophic ulcers, with the ball of the great toe being the most common site. Twelve (30.0%) patients had bone involvement. A total of 22 (55.0%) patients achieved complete resolution of the ulcer, and evidence of granulation formation was seen in 33 (82.5%) patients. The clearance of bacterial load after treatment was a significant finding. Zinc oxide paste per se was not effective, but its role as a vehicle was an asset. CONCLUSIONS: Phenytoin sodium zinc oxide paste was found to be an efficacious, cost-effective, and well-tolerated alternative therapy. Patient compliance was good. Bone involvement contributed to poor wound healing, but the clearance of bacterial load was significant.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Úlcera del Pie/tratamiento farmacológico , Lepra Dimorfa/complicaciones , Fenitoína/uso terapéutico , Óxido de Zinc/uso terapéutico , Administración Cutánea , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticonvulsivantes/administración & dosificación , Carga Bacteriana/efectos de los fármacos , Niño , Enfermedad Crónica , Fármacos Dermatológicos/administración & dosificación , Combinación de Medicamentos , Femenino , Úlcera del Pie/microbiología , Tejido de Granulación , Humanos , Masculino , Persona de Mediana Edad , Fenitoína/administración & dosificación , Cicatrización de Heridas , Adulto Joven , Óxido de Zinc/administración & dosificación
6.
Lepr Rev ; 85(4): 262-6, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25675650

RESUMEN

BACKGROUND: Many believe that the regular treatment for multibacillary (MB) leprosy cases could be shortened. A shorter treatment allowing uniformity in treatment for all cases renders case classification superfluous and therefore simplifies leprosy control. OBJECTIVE: To evaluate the association between treatment duration and the trend in bacteriological index (BI) decrease over time among patients given Uniform MDT (UMDT) compared to those given regular MDT (RMDT). METHODS: An open-label randomised clinical trial to compare the present routine treatment with one lasting six month. Patient intake was from March 2007 to February 2012. To evaluate the trend of BI as a function of time, a multilevel linear with mixed effects model was fixed to the two study groups and also four groups after stratification by BI, less than 3 and 3 or more. RESULTS: The BI fall was higher among those taking RMDT, this difference however was not statistically significant. CONCLUSION: The results presented here support the possibility of use of UMDT in the field, but further follow up is still needed for a final conclusion.


Asunto(s)
Leprostáticos/uso terapéutico , Lepra/tratamiento farmacológico , Lepra/microbiología , Carga Bacteriana/efectos de los fármacos , Brasil , Quimioterapia Combinada , Estudios de Seguimiento , Humanos , Mycobacterium leprae/efectos de los fármacos , Análisis de Regresión
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA